SLC7A11 and neoplasm: In many cancer cells, SLC7A11 is adaptively upregulated to alleviate the stress imposed by intracellular ROS and promote GSH synthesis and resistance to ferroptosis, promote tumor growth by inhibiting ferroptosis, and resist resistance to anticancer therapy (27–29).